Precipio, Inc. (NASDAQ:PRPO) Short Interest Update

Precipio, Inc. (NASDAQ:PRPO) saw a large increase in short interest in the month of April. As of April 15th, there was short interest totalling 20,200 shares, an increase of 96.1% from the March 31st total of 10,300 shares. Approximately 1.6% of the shares of the company are short sold. Based on an average daily volume of 12,200 shares, the days-to-cover ratio is presently 1.7 days.

Precipio Stock Performance

NASDAQ:PRPO opened at $6.08 on Thursday. The company has a debt-to-equity ratio of 0.02, a quick ratio of 0.60 and a current ratio of 0.73. Precipio has a 52-week low of $3.90 and a 52-week high of $10.74. The firm has a market cap of $9.14 million, a price-to-earnings ratio of -3.32 and a beta of 1.04. The business’s fifty day moving average is $6.39 and its 200 day moving average is $6.33.

Precipio (NASDAQ:PRPO) last released its quarterly earnings data on Thursday, March 27th. The biotechnology company reported ($0.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.74 by ($0.97). The company had revenue of $5.45 million for the quarter, compared to the consensus estimate of $8.01 million. Precipio had a negative net margin of 17.23% and a negative return on equity of 34.01%.

Hedge Funds Weigh In On Precipio

A hedge fund recently bought a new stake in Precipio stock. Renaissance Technologies LLC acquired a new position in Precipio, Inc. (NASDAQ:PRPO) during the fourth quarter, according to its most recent filing with the SEC. The firm acquired 10,100 shares of the biotechnology company’s stock, valued at approximately $56,000. Renaissance Technologies LLC owned about 0.68% of Precipio as of its most recent filing with the SEC. 10.45% of the stock is currently owned by institutional investors and hedge funds.

Precipio Company Profile

Precipio, Inc, a healthcare solutions company, provides diagnostic products, reagents, and services in the United States. It provides diagnostic blood cancer testing services. The company offers IV-Cell, a proprietary cell culture media that enables simultaneous culturing of four hematopoietic cell lineages; and HemeScreen, a suite of robust genetic diagnostic panels.